1-3 of 3
Marketa Kalinova
Close
Sort by
Journal Articles

Observational Study Alternating R-CHOP21 and R-Cytarabine (3+3 Cycles) for Patients with Newly Diagnosed Mantle Cell Lymphoma Not Eligible for High-Dose Therapy: A Czech Lymphoma Study Group Trial Preliminary Results

Pavel Klener, MD, PhD, Eva Fronkova, MD, PhD, Robert Pytlik, MD, PhD, Marketa Kalinova, D.Sc., PhD, Kristina Forsterova, D.Sc., PhD, David Belada, MD, Martin Simkovic, MD, David Salek, MD, PhD, Heidi Mocikova, MD, PhD, Vit Prochazka, MD, PhD, Vit Campr, MD, PhD, Radek Jaksa, MD, Jozef Kubinyi, MD, PhD, Jiri Dolezal, MD, PhD, Ass.Prof., Jan Trka, MD, PhD, Prof., Marek Trneny, MD, PhD, Prof.
Journal: Blood
Blood (2014) 124 (21): 1720.
https://doi.org/10.1182/blood.V124.21.1720.1720
Published: 2014
Journal Articles

ETV6/RUNX1 ( TEL/AML1 ) is a frequent prenatal first hit in childhood leukemia

Jan Zuna, Jozef Madzo, Ondrej Krejci, Zuzana Zemanova, Marketa Kalinova, Katerina Muzikova, Michal Zapotocky, Julia Starkova, Ondrej Hrusak, Jiri Horak, Jan Trka
Journal: Blood
Blood (2011) 117 (1): 368–369.
https://doi.org/10.1182/blood-2010-09-309070
Published: 2011
Journal Articles

Limited Reliability of Ig/TCR Based MRD Monitoring in BCR/ABL-Positive Childhood ALL: Comparison to Quantitative Fusion Transcript Detection.

Katerina Krejcikova, Katerina Muzikova, Eva Fronkova, Marketa Kalinova, Leona Reznickova, Jan Zuna, Jan Stary, Jan Trka
Journal: Blood
Blood (2006) 108 (11): 2340.
https://doi.org/10.1182/blood.V108.11.2340.2340
Published: 2006